Call Our
HELPLINE
1-800-4PD-INFO

Should Patients and Families Be Considering Tasigna (Nilotinib) Therapy for Parkinson’s Disease? The NPF Recommends Further Study but Not Clinical Use of this Investigational Drug

October 21, 2015

Should Patients and Families Be Considering Tasigna (Nilotinib) Therapy for Parkinson’s Disease? The NPF Recommends Further Study but Not Clinical Use of this Investigational Drug

Tasigna (Nilotinib) is a leukemia drug that has recently been tested for safety in a small, phase I clinical trial on about a dozen Parkinson’s disease patients. The study had positive results that certainly warrant the continuation to a phase II trial, however it is too early for patients to seek treatment outside the setting of a clinical trial. The study was very small, and it was not placebo controlled. The clinical trial process was designed primarily around patient safety, which is a critical issue with a chemotherapy drug, and this process should continue and more systematic evidence needs to be collected before we can truly understand the impact of this drug.

If you are interested in learning more about the results of this clinical trial, visit Georgetown University National Parkinson Foundation Center of Excellence.  To learn about other clinical trials, check clinical trials.gov for trials taking place in your area.

 

You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Health Center for Movement Disorders and Neurorestoration. Dr. Okun is also the author of the Amazon #1 Parkinson's Best Seller 10 Secrets to a Happier Life and 10 Breakthrough Therapies for Parkinson's Disease.